Parathyroid hormone (PTH) remains the central biomarker to classify CKD-metabolic bone disease (CKD-MBD) in hemodialysis patients. While PTH-values are known to be associated with adverse outcomes, interventional studies have failed to show a benefit of pharmacological modulation of PTH levels on hard clinical outcomes. To address this gap, the investigators explored alternative markers of bone metabolism, vascular calcification and inflammation in association to prospective event patterns.
Study Type
OBSERVATIONAL
Enrollment
475
Medical University Graz
Graz, Styria, Austria
Mortality
All-causes, the date of death will be recorded.
Time frame: 1, 2 and 3 years
Cause-specific mortality
The cause of death will be recorded.
Time frame: 1, 2 and 3 years
MACE
The number of participants with, the date and cause of MACE (The 4-point MACE is a composite outcome measure of non-fatal stroke and myocardial infarction, urgent angina and fatal cardiovascular events) will be recorded from medical record review.
Time frame: 1, 2 and 3 years
The number of participants with hospitalisation for Infection
The number and dates of hospitalisations for any infectious diseases (such as pneumonia, sepsis or urinary tract infection) will be recorded from medical record review.
Time frame: 1, 2 and 3 years
The number of participants with hospitalisation for Heart failure
The number and dates of hospitalisations for heart failure (such as acute heart failure or decompensated chronic heart failure) will be recorded from medical record review.
Time frame: 1, 2 and 3 years
The number of participants with Fractures
The number and dates of fractures (classified by anatomical site, such as hip, vertebral, or upper limb) will be recorded from medical record review.
Time frame: 1, 2 and 3 years
The number of participants with Bleeding events
The number and dates of bleeding events (classified as major or minor according to ISTH definition) will be recorded from medical record review.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 1, 2 and 3 years
The number of participants with Interventions for vascular diseases
The number and dates of surgical and endovascular interventions (such as revascularization, bypass or amputation) for atherosclerotic cardiovascular diseases (such as coronary and peripheral artery disease) will be recorded from medical record review.
Time frame: 1, 2 and 3 years